The Pharma Letter19h
Zai Lab prices public offering to raise $200 million
Zai Lab has priced its public offering at $25.50 per share, targeting $200 million for corporate purposes. The fundraising ...
The Pharma Letter19h
UK regulator approves adapted Novavax jab
The MHRA has approved Novavax’s updated Nuvaxovid vaccine for the latest subvariant in individuals aged 12 and older. This ...
The Pharma Letter23h
Sanofi investing 40 million euros on expanding Lyon Gerland site
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...
The Pharma Letter20h
Celltrion acquires Swiss firm iQone Healthcare
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty ...
The Pharma Letter22h
Vaccine firms slide on ‘catastrophic’ RFK Jr nomination
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to ...
The Pharma Letter20h
EMA/CHMP November recommendations include Leqembi U-turn
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...
The Pharma Letter23h
Blenrep results ‘transformative’, GSK says
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
The Pharma Letter19h
J&J seeks court's blessing for controversial rebate plan
Johnson & Johnson has filed a lawsuit seeking validation of its rebate model for 340B drugs, which offers post-sale rebates instead of upfront discounts. The initiative, criticized by hospitals and ...